LOGIN  |  REGISTER
Viking Therapeutics
Terns Pharmaceuticals

Warby Parker Announces Second Quarter 2023 Results

August 09, 2023 | Last Trade: US$22.65 0.63 2.86
  • Net revenue increased 11.0% year over year to $166.1 million
  • Average Revenue per Customer increased 9.2% year over year to $277
  • Raises full year 2023 outlook

NEW YORK / Aug 09, 2023 / Business Wire / Warby Parker Inc. (NYSE: WRBY) (“Warby Parker” or the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the second quarter ended June 30, 2023.

“We delivered another quarter of double-digit revenue growth and strong adjusted EBITDA margin expansion,” said Co-Founder and Co-CEO Dave Gilboa. “The work we’ve done realigning our expense structure is enabling us to balance improving profitability with reinvesting in the business to drive sustained market share gains long term.”

“Our stores are playing an increasingly important role in attracting new consumers to our brand and extending the reach and availability of our holistic vision offering,” added Co-Founder and Co-CEO Neil Blumenthal. “Equally important, our stores continue to generate strong margins and high returns on capital even as the optical industry has recently experienced demand headwinds. We opened 13 new stores in the second quarter, remain on track to open 40 new stores this year, and believe we have the potential to reach at least 900 locations over time.”

Second Quarter 2023 Year Over Year Highlights

  • Net revenue increased $16.5 million, or 11.0%, to $166.1 million.
  • GAAP net loss improved $16.2 million to $15.9 million.
  • Adjusted EBITDA(1) increased $8.2 million to $14.2 million and adjusted EBITDA margin(1) improved 4.5 points from 4.0% to 8.5%.

Second Quarter 2023 Year Over Year Financial Results

  • Net revenue increased $16.5 million, or 11.0%, to $166.1 million.
  • Average Revenue per Customer increased 9.2% to $277. Active Customers increased 1.2% to 2.28 million.
  • Gross profit increased 5.0% to $90.6 million.
  • Gross margin was 54.6% compared to 57.7% in the prior year period. The decline in gross margin was primarily driven by the increased penetration of contact lenses, which carry lower gross margins than eyeglasses; an increase in salary and benefit costs associated with optometrists as we scale our eye exam offering across our fleet, to 169 exam locations, up from 127 in the prior year period; and the impact of the growth in store count driving higher store occupancy and depreciation costs.
  • Selling, general and administrative expenses (“SG&A”) was 65.5% of revenue, down from 79.2% of revenue in the prior year period, reflecting a decline of $9.6 million to $108.9 million, primarily driven by lower stock-based compensation and reduced marketing costs, partially offset by increased technology costs related to the implementation of our new ERP system. Adjusted SG&A(1) decreased to $86.8 million, or 52.2% of revenue, down from $88.5 million, or 59.2% of revenue in the prior year period.
  • GAAP net loss decreased $16.2 million to $15.9 million, primarily as a result of the decrease in SG&A described above.
  • Adjusted EBITDA(1) increased $8.2 million to $14.2 million and adjusted EBITDA margin(1) improved 4.5 points to 8.5%.
  • Opened 13 new stores during the quarter, ending Q2 with 217 stores.

Balance Sheet Highlights

Warby Parker ended the second quarter of 2023 with $212.7 million in cash and cash equivalents.

2023 Outlook

For the full year 2023, Warby Parker is revising guidance to be as follows:

  • Net revenue of $655 to $664 million, representing growth of 9.5% to 11.0% versus full year 2022.
  • Adjusted EBITDA(1) of approximately $52 million, or adjusted EBITDA margin(1) of 7.9%.
  • On track for 40 new store openings this year.

“We are pleased to build upon our early success this year and deliver another quarter of outperformance, both from a topline and adjusted EBITDA perspective,” said Chief Financial Officer Steve Miller. “Given our better than anticipated results in the first half of 2023, we are raising our full year guidance. While growth for the broader optical industry remains slow, our proven ability to capture market share despite these difficult operating conditions gives us confidence.”

The guidance and forward-looking statements made in this press release and on our conference call are based on management's expectations as of the date of this press release.

(1) Please see the reconciliation of non-GAAP financial measures to the most comparable GAAP financial measure in the section titled “Non-GAAP Financial Measures” below.

Webcast and Conference Call

A conference call to discuss Warby Parker’s second quarter 2023 results, as well as third quarter and full year 2023 outlook, is scheduled for 8:00 a.m. ET today. To participate, please dial 833-470-1428 from the U.S. or 404-975-4839 from international locations. The conference passcode is 514708. A live webcast of the conference call will be available on the investors section of the Company’s website at investors.warbyparker.com where presentation materials will also be posted prior to the conference call. A replay will be made available online approximately two hours following the live call for a period of 90 days.

Forward-Looking Statements

This press release and the related conference call, webcast and presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, expectations of future operating results or financial performance, including expectations regarding achieving profitability and growth in our e-commerce channel, delivering stakeholder value, growing market share, and our guidance for the quarter ending September 30, 2023 and year ending December 31, 2023; expectations regarding the number of new store openings during the year ending December 31, 2023; management’s plans, priorities, initiatives and strategies; and expectations regarding growth of our business. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “toward,” “will,” or “would,” or the negative of these words or other similar terms or expressions. You should not put undue reliance on any forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved, if at all.

Forward-looking statements are based on information available at the time those statements are made and are based on current expectations, estimates, forecasts, and projections as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control, that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements. These risks and uncertainties include our ability to manage our future growth effectively; our expectations regarding cost of goods sold, gross margin, channel mix, customer mix, and selling, general, and administrative expenses; increases in component and shipping costs and changes in supply chain; our reliance on our information technology systems and enterprise resource planning systems for our business to effectively operate and safeguard confidential information; our ability to engage our existing customers and obtain new customers; planned new retail stores in 2023 and going forward; an overall decline in the health of the economy and other factors impacting consumer spending, such as recessionary conditions, inflation and government instability; our ability to compete successfully; our ability to manage our inventory balances and shrinkage; the growth of our brand awareness; our ability to recruit and retain optometrists, opticians, and other vision care professionals; a resurgence of COVID-19 or the spread of new infectious diseases; the effects of seasonal trends on our results of operations; our ability to stay in compliance with extensive laws and regulations that apply to our business and operations; our ability to adequately maintain and protect our intellectual property and proprietary rights; our reliance on third parties for our products, operation and infrastructure; our duties related to being a public benefit corporation; the ability of our Co-Founders and Co-CEOs to exercise significant influence over all matters submitted to stockholders for approval; the effect of our multi-class structure on the trading price of our Class A common stock; and the increased expenses associated with being a public company. Additional information regarding these and other risks and uncertainties that could cause actual results to differ materially from the Company's expectations is included in our most recent reports filed with the SEC on Form 10-K and Form 10-Q. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

Additional information regarding these and other factors that could affect the Company’s results is included in the Company’s SEC filings, which may be obtained by visiting the SEC's website at www.sec.gov. Information contained on, or that is referenced or can be accessed through, our website does not constitute part of this document and inclusions of any website addresses herein are inactive textual references only.

Glossary

Active Customer is defined as a unique customer that has made at least one purchase of any product or service in the preceding 12-month period.

Average Revenue per Customer is defined as net revenue for a given period divided by the number of Active Customers as of the end of that same period.

Non-GAAP Financial Measures

We use adjusted EBITDA, adjusted EBITDA margin, adjusted net income, adjusted earnings per share, adjusted cost of goods sold (“adjusted COGS”), adjusted gross margin, adjusted gross profit, and adjusted selling, general, and administrative expenses (“adjusted SG&A”) as important indicators of our operating performance. Collectively, we refer to these non-GAAP financial measures as our “Non-GAAP Measures.” The Non-GAAP Measures, when taken collectively with our GAAP results, may be helpful to investors because they provide consistency and comparability with past financial performance and assist in comparisons with other companies, some of which use similar non-GAAP financial information to supplement their GAAP results.

Adjusted EBITDA is defined as net income (loss) before interest and other income, taxes, and depreciation and amortization as further adjusted for asset impairment costs, stock-based compensation expense and related employer payroll taxes, amortization of cloud-based software implementation costs, non-cash charitable donations, and non-recurring costs such as major system implementation costs. Adjusted EBITDA margin is defined as adjusted EBITDA divided by net revenue.

Adjusted net income (loss) is defined as net income (loss) adjusted for stock-based compensation expense and related employer payroll taxes, non-cash charitable donations, and non-recurring costs such as major system implementation costs, and as further adjusted for estimated income tax on such adjusted items.

Adjusted earnings (loss) per share is defined as adjusted net income (loss) divided by adjusted weighted average shares outstanding.

Adjusted COGS is defined as cost of goods sold adjusted for stock-based compensation expense and related employer payroll taxes.

Adjusted gross profit is defined as net revenue minus adjusted COGS. Adjusted gross margin is defined as adjusted gross profit divided by net revenue.

Adjusted SG&A is defined as SG&A adjusted for stock-based compensation expense and related employer payroll taxes, non-cash charitable donations, and non-recurring costs such as major system implementation costs.

The Non-GAAP Measures are presented for supplemental informational purposes only. A reconciliation of historical GAAP to Non-GAAP financial information is included under “Selected Financial Information” below.

We have not reconciled our adjusted EBITDA margin guidance to GAAP net income (loss) margin, or net margin, or adjusted EBITDA guidance to GAAP net income (loss) because we do not provide guidance for GAAP net margin or GAAP net income (loss) due to the uncertainty and potential variability of stock-based compensation and taxes, which are reconciling items between GAAP net margin and adjusted EBITDA margin and GAAP net income (loss) and adjusted EBITDA, respectively. Because such items cannot be reasonably provided without unreasonable efforts, we are unable to provide a reconciliation of the adjusted EBITDA margin guidance to GAAP net margin and adjusted EBITDA guidance to GAAP net income (loss). However, such items could have a significant impact on GAAP net margin and GAAP net income (loss).

About Warby Parker

Warby Parker (NYSE: WRBY) was founded in 2010 with a mission to inspire and impact the world with vision, purpose, and style–without charging a premium for it. Headquartered in New York City, the co-founder-led lifestyle brand pioneers ideas, designs products, and develops technologies that help people see, from designer-quality prescription glasses (starting at $95) and contacts, to eye exams and vision tests available online and in more than 200 retail stores across the U.S. and Canada.

Warby Parker aims to demonstrate that businesses can scale, do well, and do good in the world. Ultimately, the brand believes in vision for all, which is why for every pair of glasses or sunglasses sold, they distribute a pair to someone in need through their Buy a Pair, Give a Pair program. To date, Warby Parker has worked alongside its nonprofit partners to distribute more than 13 million glasses to people in need.

Selected Financial Information

Warby Parker Inc. and Subsidiaries

Consolidated Balance Sheets (Unaudited)

(Amounts in thousands, except share data)

   

 

June 30,
2023

 

December
31, 2022

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

212,656

 

 

$

208,585

 

Accounts receivable, net

 

1,177

 

 

 

1,435

 

Inventory

 

59,833

 

 

 

68,848

 

Prepaid expenses and other current assets

 

14,377

 

 

 

15,700

 

Total current assets

 

288,043

 

 

 

294,568

 

 

 

 

 

Property and equipment, net

 

143,606

 

 

 

138,628

 

Right-of-use lease assets

 

122,355

 

 

 

127,014

 

Other assets

 

7,705

 

 

 

8,497

 

Total assets

$

561,709

 

 

$

568,707

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

23,772

 

 

$

20,791

 

Accrued expenses

 

42,759

 

 

 

58,222

 

Deferred revenue

 

18,953

 

 

 

25,628

 

Current lease liabilities

 

22,598

 

 

 

22,546

 

Other current liabilities

 

2,351

 

 

 

2,370

 

Total current liabilities

 

110,433

 

 

 

129,557

 

 

 

 

 

Non-current lease liabilities

 

147,748

 

 

 

150,832

 

Other liabilities

 

1,466

 

 

 

1,672

 

Total liabilities

 

259,647

 

 

 

282,061

 

Commitments and contingencies

 

 

 

Stockholders’ equity:

 

 

 

Common stock, $0.0001 par value; Class A: 750,000,000 shares authorized at June 30, 2023 and December 31, 2022, 97,142,756 and 96,115,202 issued and outstanding at June 30, 2023 and December 31, 2022, respectively; Class B: 150,000,000 shares authorized at June 30, 2023 and December 31, 2022, 19,398,920 and 19,223,572 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively, convertible to Class A on a one-to-one basis

 

12

 

 

 

12

 

Additional paid-in capital

 

933,786

 

 

 

890,915

 

Accumulated deficit

 

(630,371

)

 

 

(603,634

)

Accumulated other comprehensive loss

 

(1,365

)

 

 

(647

)

Total stockholders’ equity

 

302,062

 

 

 

286,646

 

Total liabilities and stockholders’ equity

$

561,709

 

 

$

568,707

 

Warby Parker Inc. and Subsidiaries

Consolidated Statements of Operations (Unaudited)

(Amounts in thousands, except share and per share data)

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

Net revenue

$

166,093

 

 

$

149,624

 

 

$

338,061

 

 

$

302,842

 

Cost of goods sold

 

75,458

 

 

 

63,277

 

 

 

152,635

 

 

 

126,849

 

Gross profit

 

90,635

 

 

 

86,347

 

 

 

185,426

 

 

 

175,993

 

 

 

 

 

 

 

 

 

Selling, general, and administrative expenses

 

108,865

 

 

 

118,428

 

 

 

216,086

 

 

 

241,814

 

Loss from operations

 

(18,230

)

 

 

(32,081

)

 

 

(30,660

)

 

 

(65,821

)

 

 

 

 

 

 

 

 

Interest and other income (loss), net

 

2,281

 

 

 

(38

)

 

 

4,160

 

 

 

108

 

 

 

 

 

 

 

 

 

Loss before income taxes

 

(15,949

)

 

 

(32,119

)

 

 

(26,500

)

 

 

(65,713

)

Provision for income taxes

 

(24

)

 

 

47

 

 

 

237

 

 

 

586

 

Net loss

$

(15,925

)

 

$

(32,166

)

 

$

(26,737

)

 

$

(66,299

)

 

 

 

 

 

 

 

 

Net loss per share attributable to common stockholders, basic and diluted

$

(0.14

)

 

$

(0.28

)

 

$

(0.23

)

 

$

(0.58

)

Weighted average shares used in computing net loss per share attributable to common stockholders, basic and diluted

 

116,792,223

 

 

 

114,679,892

 

 

 

116,477,573

 

 

 

114,393,420

 

Warby Parker Inc. and Subsidiaries

Consolidated Statements of Cash Flows (Unaudited)

(Amounts in thousands)

 

Six Months Ended June 30,

 

 

2023

 

 

 

2022

 

Cash flows from operating activities

 

 

 

Net loss

$

(26,737

)

 

$

(66,299

)

Adjustments to reconcile net loss to net cash provided by operating activities:

 

 

 

Depreciation and amortization

 

18,424

 

 

 

14,605

 

Stock-based compensation

 

37,792

 

 

 

53,908

 

Non-cash charitable contribution

 

600

 

 

 

3,270

 

Asset impairment charges

 

650

 

 

 

412

 

Amortization of cloud-based software implementation costs

 

826

 

 

 

 

Change in operating assets and liabilities:

 

 

 

Accounts receivable, net

 

259

 

 

 

89

 

Inventory

 

9,048

 

 

 

(13,704

)

Prepaid expenses and other assets

 

1,301

 

 

 

(2,385

)

Accounts payable

 

2,148

 

 

 

1,461

 

Accrued expenses

 

(11,619

)

 

 

(8,367

)

Deferred revenue

 

(6,684

)

 

 

(3,762

)

Other current liabilities

 

(21

)

 

 

233

 

Right-of-use lease assets and current and non-current lease liabilities

 

1,614

 

 

 

3,985

 

Other liabilities

 

(206

)

 

 

1,930

 

Net cash provided by (used in) operating activities

 

27,395

 

 

 

(14,624

)

Cash flows from investing activities

 

 

 

Purchases of property and equipment

 

(24,610

)

 

 

(31,869

)

Net cash used in investing activities

 

(24,610

)

 

 

(31,869

)

Cash flows from financing activities

 

 

 

Proceeds from stock option exercises

 

843

 

 

 

228

 

Proceeds from shares issued in connection with employee stock purchase plan

 

1,124

 

 

 

1,754

 

Net cash provided by financing activities

 

1,967

 

 

 

1,982

 

Effect of exchange rates on cash

 

(681

)

 

 

(302

)

Net change in cash and cash equivalents

 

4,071

 

 

 

(44,813

)

Cash and cash equivalents, beginning of period

 

208,585

 

 

 

256,416

 

Cash and cash equivalents, end of period

$

212,656

 

 

$

211,603

 

Supplemental disclosures

 

 

 

Cash paid for income taxes

$

326

 

 

$

297

 

Cash paid for interest

 

110

 

 

 

62

 

Cash paid for amounts included in the measurement of lease liabilities

 

17,530

 

 

 

13,858

 

Non-cash investing and financing activities:

 

 

 

Purchases of property and equipment included in accounts payable and accrued expenses

$

3,351

 

 

$

3,579

 

Warby Parker Inc. and Subsidiaries

Reconciliation of GAAP to Non-GAAP Measures (Unaudited)

The following table reconciles adjusted EBITDA and adjusted EBITDA margin to the most directly comparable GAAP measure, which is net loss:

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

 

unaudited (in thousands)

 

unaudited (in thousands)

Net loss

$

(15,925

)

 

$

(32,166

)

 

$

(26,737

)

 

$

(66,299

)

Adjusted to exclude the following:

 

 

 

 

 

 

 

Interest and other loss, net

 

(2,281

)

 

 

38

 

 

 

(4,160

)

 

 

(108

)

Provision for income taxes

 

(24

)

 

 

47

 

 

 

237

 

 

 

586

 

Depreciation and amortization expense

 

9,284

 

 

 

7,694

 

 

 

18,424

 

 

 

14,605

 

Asset impairment charges

 

255

 

 

 

186

 

 

 

650

 

 

 

412

 

Stock-based compensation expense(1)

 

18,164

 

 

 

26,867

 

 

 

38,030

 

 

 

54,244

 

Non-cash charitable donation(2)

 

600

 

 

 

3,270

 

 

 

600

 

 

 

3,270

 

Amortization of cloud-based software implementation costs(3)

 

463

 

 

 

 

 

 

826

 

 

 

 

ERP implementation costs(4)

 

3,639

 

 

 

 

 

 

4,042

 

 

 

 

Adjusted EBITDA

 

14,175

 

 

 

5,936

 

 

 

31,912

 

 

 

6,710

 

Adjusted EBITDA margin

 

8.5

%

 

 

4.0

%

 

 

9.4

%

 

 

2.2

%

(1) Represents expenses related to the Company’s equity-based compensation programs and related employer payroll taxes, which may vary significantly from period to period depending upon various factors including the timing, number, and the valuation of awards granted, and vesting of awards including the satisfaction of performance conditions. For the three months ended June 30, 2023 and 2022, the amount includes $0.2 million and $0.1 million, respectively, of employer payroll costs associated with releases of RSUs and option exercises. For the six months ended June 30, 2023 and 2022, the amount includes $0.2 million and $0.3 million, respectively, of employer payroll costs associated with releases of RSUs and option exercises.

(2) Represents charitable expense recorded in connection with the donation of 56,938 shares of Class A common stock to charitable donor advised funds in June 2023 and 178,572 shares of Class A common stock in May 2022 to the Warby Parker Impact Foundation.

(3) Represents the amortization of costs capitalized in connection with the implementation of cloud-based software.

(4) Represents internal and external non-capitalized costs related to the implementation of our new Enterprise Resource Planning (“ERP”) system.

Warby Parker Inc. and Subsidiaries

Reconciliation of GAAP to Non-GAAP Measures (Unaudited)

The following table presents our non-GAAP, or adjusted, financial measures for the periods presented as a percentage of revenue. Each cost and operating expense is adjusted for stock-based compensation expense and related employer payroll taxes and ERP implementation costs, if applicable.

 

Reported

 

Adjusted

 

Reported

 

Adjusted

 

Three Months Ended June 30,

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

Six Months Ended June 30,

 

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

 

(unaudited, in thousands)

 

(unaudited, in thousands)

 

(unaudited, in thousands)

 

(unaudited, in thousands)

Cost of goods sold

$

75,458

 

 

$

63,277

 

 

$

75,162

 

 

$

63,042

 

 

$

152,635

 

 

$

126,849

 

 

$

152,141

 

 

$

126,379

 

% of Revenue

 

45.4

%

 

 

42.3

%

 

 

45.3

%

 

 

42.1

%

 

 

45.2

%

 

 

41.9

%

 

 

45.0

%

 

 

41.7

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

$

90,635

 

 

$

86,347

 

 

$

90,931

 

 

$

86,582

 

 

$

185,426

 

 

$

175,993

 

 

$

185,920

 

 

$

176,463

 

% of Revenue

 

54.6

%

 

 

57.7

%

 

 

54.7

%

 

 

57.9

%

 

 

54.8

%

 

 

58.1

%

 

 

55.0

%

 

 

58.3

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general, and administrative expenses

$

108,865

 

 

$

118,428

 

 

$

86,758

 

 

$

88,526

 

 

$

216,086

 

 

$

241,814

 

 

$

173,908

 

 

$

184,770

 

% of Revenue

 

65.5

%

 

 

79.2

%

 

 

52.2

%

 

 

59.2

%

 

 

63.9

%

 

 

79.8

%

 

 

51.4

%

 

 

61.0

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net (loss) income

$

(15,925

)

 

$

(32,166

)

 

$

4,553

 

 

$

(1,398

)

 

$

(26,737

)

 

$

(66,299

)

 

$

11,408

 

 

$

(5,744

)

% of Revenue

 

(9.6

)%

 

 

(21.5

)%

 

 

2.7

%

 

 

(0.9

)%

 

 

(7.9

)%

 

 

(21.9

)%

 

 

3.4

%

 

 

(1.9

)%

Warby Parker Inc. and Subsidiaries

Reconciliation of GAAP to Non-GAAP Measures (Unaudited)

The following table reflects a reconciliation of each non-GAAP, or adjusted, financial measure to its most directly comparable financial measure prepared in accordance with GAAP:

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

 

(unaudited, in thousands)

 

(unaudited, in thousands)

Cost of goods sold

$

75,458

 

 

$

63,277

 

 

$

152,635

 

 

$

126,849

 

Adjusted to exclude the following:

 

 

 

 

 

 

 

Stock-based compensation expense(1)

 

296

 

 

 

235

 

 

 

494

 

 

 

470

 

Adjusted cost of goods sold

$

75,162

 

 

$

63,042

 

 

$

152,141

 

 

$

126,379

 

 

 

 

 

 

 

 

 

Gross profit

$

90,635

 

 

$

86,347

 

 

$

185,426

 

 

$

175,993

 

Adjusted to exclude the following:

 

 

 

 

 

 

 

Stock-based compensation expense(1)

 

296

 

 

 

235

 

 

 

494

 

 

 

470

 

Adjusted gross profit

$

90,931

 

 

$

86,582

 

 

$

185,920

 

 

$

176,463

 

 

 

 

 

 

 

 

 

Selling, general, and administrative expenses

$

108,865

 

 

$

118,428

 

 

$

216,086

 

 

$

241,814

 

Adjusted to exclude the following:

 

 

 

 

 

 

 

Stock-based compensation expense(1)

 

17,868

 

 

 

26,632

 

 

 

37,536

 

 

 

53,774

 

Non-cash charitable donation(2)

 

600

 

 

 

3,270

 

 

 

600

 

 

 

3,270

 

ERP implementation costs(3)

 

3,639

 

 

 

 

 

 

4,042

 

 

 

 

Adjusted selling, general, and administrative expenses

$

86,758

 

 

$

88,526

 

 

$

173,908

 

 

$

184,770

 

 

 

 

 

 

 

 

 

Net loss

$

(15,925

)

 

$

(32,166

)

 

$

(26,737

)

 

$

(66,299

)

Provision for income taxes

 

(24

)

 

 

47

 

 

 

237

 

 

 

586

 

Loss before income taxes

 

(15,949

)

 

 

(32,119

)

 

 

(26,500

)

 

 

(65,713

)

Adjusted to exclude the following:

 

 

 

 

 

 

 

Stock-based compensation expense(1)

 

18,164

 

 

 

26,867

 

 

 

38,030

 

 

 

54,244

 

Non-cash charitable donation(2)

 

600

 

 

 

3,270

 

 

 

600

 

 

 

3,270

 

ERP implementation costs(3)

 

3,639

 

 

 

 

 

 

4,042

 

 

 

 

Adjusted provision for income taxes(4)

 

(1,901

)

 

 

584

 

 

 

(4,764

)

 

 

2,415

 

Adjusted net income (loss)

$

4,553

 

 

$

(1,398

)

 

$

11,408

 

 

$

(5,784

)

 

 

 

 

 

 

 

 

Adjusted weighted average shares - diluted

 

117,352,024

 

 

 

114,679,892

 

 

 

117,260,647

 

 

 

114,393,420

 

Adjusted diluted earnings (loss) per share

$

0.04

 

 

$

(0.01

)

 

$

0.10

 

 

$

(0.05

)

(1) Represents expenses related to the Company’s equity-based compensation programs and related employer payroll taxes, which may vary significantly from period to period depending upon various factors including the timing, number, and the valuation of awards granted, and vesting of awards including the satisfaction of performance conditions. For the three months ended June 30, 2023 and 2022, the amount includes $0.2 million and $0.1 million, respectively, of employer payroll costs associated with releases of RSUs and option exercises. For the six months ended June 30, 2023 and 2022, the amount includes $0.2 million and $0.3 million, respectively, of employer payroll costs associated with releases of RSUs and option exercises.

(2) Represents charitable expense recorded in connection with the donation of 56,938 shares of Class A common stock to charitable donor advised funds in June 2023 and 178,572 shares of Class A common stock in May 2022 to the Warby Parker Impact Foundation.

(3) Represents internal and external non-capitalized costs related to the implementation of our new ERP system.

(4) The adjusted provision for income taxes is based on long-term estimated annual effective tax rate 29.46% in both 2023 and 2022. The Company may adjust its adjusted tax rate as additional information becomes available or events occur which may materially affect this rate, including impacts from the rapidly evolving global tax environment, significant changes in our geographic mix, merger and acquisition activity, or changes in our business outlook.

Terns Pharmaceuticals

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB